Gilead quarterly profit beats Street estimates, revenue up 5%
By Deena Beasley
Aug 8 (Reuters) -Gilead Sciences GILD.O on Thursday reported second-quarter profit that handily beat Wall Street estimates, driven by lower operating expenses and higher product sales, and the drugmaker raised its outlook for full-year earnings.
The Foster City, California-based company posted a quarterly profit of $2.01 per share excluding items, on revenue of $7 billion, up from $1.34 a share and revenue of $6.6 billion in the year-ago quarter.
Wall Street analysts had expected an adjusted profit of $1.60 per share on revenue of $6.72 billion, according to LSEG data.
“It was a very strong quarter of commercial execution," CEO Daniel O'Day told Reuters in an interview, citing recent data showing that the company's long-acting injectable drug lenacapavir was more effective in preventing HIV infection in women compared to a daily pill.
He said the company also looks forward to a potential U.S. launch of seladelpar, a liver drug acquired with Gilead's purchase earlier this year of CymaBay, for primary biliary cholangitis. The U.S. Food and Drug Administration is slated to decide on the drug's approval by next Wednesday.
Quarterly sales of HIV drug Biktarvy rose 8% to $3.2 billion, which was in line with analysts' estimates. Sales of its COVID-19 treatment Veklury fell 16% to $214 million, but still came in well above Wall Street expectations of $190 million.
Oncology sales rose 15% to $841 million, while sales of liver disease drugs rose 17% to $832 million.
For full-year 2024, Gilead said it still expects product sales of $27.1 billion to $27.5 billion, but raised its adjusted profit estimate to $3.60 to $3.90 a share from a previous $3.45 to $3.85 a share.
Analysts have projected 2024 earnings per share of $3.75 on revenue of $27.58 billion.
Reporting By Deena Beasley
Editing by Bill Berkrot
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
